Back to top
more

Esperion Therapeutics (ESPR)

(Delayed Data from NSDQ)

$1.71 USD

1.71
2,537,410

-0.05 (-2.84%)

Updated Aug 27, 2024 04:00 PM ET

After-Market: $1.70 -0.01 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Is a Beat in Store for Ionis (IONS) This Earnings Season?

Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

    What's in the Cards for Endo (ENDP) this Earnings Season?

    Endo International plc (ENDP) remains focused on providing updates on its restructuring efforts across the Generics product as well as its manufacturing facility network in Q2.

      Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?

      Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q2.

        The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

        The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

          Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4%

          Esperion Therapeutics, Inc. (ESPR) shares jumped a little above 10% in the last trading session.

            Megan Sanks headshot

            Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today

            In a week full of good news for Esperion Therapeutics (ESPR), shares of the company closed the day up 10% to $48.28 per share.

              Esperion's Combo Cholesterol Candidate Enters Phase III

              Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.

                The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

                The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

                  Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%

                  Esperion Therapeutics, Inc. (ESPR) moved big last session, as its shares rose above 8% on the day.